Tag Archives: glioblastoma

Modulight Spotlights: LASER-SHARP RESEARCH – March 2024

 Modulight Spotlights: LASER-SHARP RESEARCH – March 2024 Glioblastoma is the most aggressive type of brain tumor. It is hard to treat because of its invasion into functioning brain tissues, limited drug delivery due to blood-brain-barrier, and evolved treatment resistance. To address these challenges, a light-activated nanoformulation, called nanoVP, was developed for glioblastoma in a new study co-led by John Quinlan and Collin Inglut in Dr. Huang’s team at the University of Maryland. Published in a prestigious journal Advanced Science, this novel therapy resulted in an improved tumor control and survival Continue reading →

Carrier-Free, Amorphous Verteporfin Nanodrug for Enhanced Photodynamic Cancer Therapy and Brain Drug Delivery

Published in: Advanced Science Authors: John A. Quinlan, Collin T. Inglut, Payal Srivastava, Idrisa Rahman, Jillian Stabile, Brandon Gaitan, Carla Arnau Del Valle, Kaylin Baumiller, Anandita Gaur, Wen-An Chiou, Baktiar Karim, Nina Connolly, Robert W. Robey, Graeme F. Woodworth, Michael M. Gottesman, Huang-Chiao Huang University of Maryland  Published in: Advanced Science Authors: John A. Quinlan, Collin T. Inglut, Payal Srivastava, Idrisa Rahman, Jillian Stabile, Brandon Gaitan, Carla Arnau Del Valle, Kaylin Baumiller, Anandita Gaur, Wen-An Chiou, Baktiar Karim, Nina Connolly, Robert W. Robey, Graeme F. Woodworth, Michael M. Gottesman, Huang-Chiao Huang University of Maryland Glioblastoma (GBM) is hard to treat due to cellular invasion into functioning brain tissues, limited drug delivery, and evolved treatment resistance. Recurrence is nearly universal even after surgery, chemotherapy, and radiation. Photodynamic therapy (PDT) involves photosensitizer administration followed by light activation to generate reactive oxygen species at tumor sites, thereby killing cells or Continue reading →

Automated drug detection and dynamic measurement prioritization with medical laser platform

Published in: SPIE BIOS 2024 Authors: Henri Auvinen, Lassi Luokkanen, Zoe Ylöniemi, Natalia Leinonen, Ana Colucci, Petteri Uusimaa  Published in: SPIE BIOS 2024 Authors: Henri Auvinen, Lassi Luokkanen, Zoe Ylöniemi, Natalia Leinonen, Ana Colucci, Petteri Uusimaa Monitoring treatment through spectral data enables adjusting treatment in real-time for each patient separately, in line with the trend for personalized medicine. Modulight ML7710 laser can simultaneously measure spectral data from up to 8 different locations in tumor tissue. The laser with this optical monitoring feature is currently being tested in glioblastoma trials in Germany where patients receive photoimmunotherapy and treatment is tailored through spectral monitoring of Continue reading →

Light penetration depth in brain with different photosensitizers

  Motivation for the study Glioblastoma is the most aggressive and lethal brain cancer with an average prognosis of 15 months. Fluorescence-guided surgery (FGS) for glioblastoma was FDA-approved in 2017, while photodynamic therapy (PDT) remains an active area of clinical investigation with very promising results so far. The aim of PDT is to eradicate the invasive cancer cells within 2 cm of the resected area where the glioblastoma most often recurs. However, a significant hurdle of this therapy modality is the limited light penetration depth Continue reading →Customer case Research by: University of Maryland, Optical Therapeutics & Nanotechnology Laboratory led by Prof. Huang. Research focuses on precision cancer nanomedicine, drug delivery strategies, overcoming cancer resistance, mechanism-based combination therapies, site-directed photochemistry and fluorescence diagnostics. Modulight has started a joint R&D program with Dr. Huang lab to study novel EGFR-targeted combination therapy/diagnostic agent PIC-Nal-IRI developed by Huang lab. Modulight products: ML6600 laser system (635 nm and 689 nm). Professor Huang-Chiao Huang Laser use: Targeted photodynamic therapy/photoimmunotherapy with benzoporphyrin derivative (BPD) & 5-aminolevulinic acid (5-ALA) photosensitizers. Continue reading →

ML7710 for glioblastoma treatment

Background   Professor Stummer on glioblastoma surgeries and iPDT:   Treatment protocol 20 patients were treated. 5-ALA (Gliolan) was administered at a dosage of 20 mg/kg body weight 4 hours before anesthesia. Craniotomy was performed using FGR, with aim of maximal safe resection of the fluorescent tumor. Once there was no visible fluorescence or only tumor-infiltrated fluorescence in the eloquent areas left, PDT was performed. 1-4 cylindrical diffuser were strategically inserted depending on the size and architecture of the resection cavity and fixed to a Continue reading →Customer case Research by: University Hospital Münster provides cutting-edge medical treatments for patients all over the world. The department of neurosurgery provides a full spectrum of neurosurgical care with interdisciplinary vascular and neuro-oncological specialization. Modulight products: ML7710, ML7710i Laser use: Randomized controlled PDT trials for both newly diagnosed and recurrent glioblastoma, as well as compassionate care for terminal glioblastoma patients. Link to the study: Professor Walter Stummer, MD, PhD Research topics: Professor Stummer is a world leader in his research fields, which include vascular neurosurgery, microneurosurgery, Continue reading →

Combination of ALA-induced fluorescence-guided resection and intraoperative open photodynamic therapy for recurrent glioblastoma: case series on a promising dual strategy for local tumor control

Published in: Journal of Neurosurgery Authors: Stephanie Schipmann, Michael Müther, Louise Stögbauer, Sebastian Zimmer, Benjamin Brokinkel, Markus Holling, Oliver Grauer, Eric Suero Molina, Nils Warneke, Walter Stummer    Published in: Journal of Neurosurgery Authors: Stephanie Schipmann, Michael Müther, Louise Stögbauer, Sebastian Zimmer, Benjamin Brokinkel, Markus Holling, Oliver Grauer, Eric Suero Molina, Nils Warneke, Walter Stummer   Report on results from intraoperative open PDT compassionate care of 20 recurrent glioblastoma patients. ML7710 was used only for PDT (Zeiss surgical microscope used for fluorescence visualization of PPIX). Results suggest that combining PDT with 5-ALA FGR (fluorescence-guided resection) is effective (effect of PDT was seen in 80% of patients) and safe (only one adverse event was Continue reading →